STOCK TITAN
  1. Home
  2. Sec-filings
  3. TWST
  4. [Form 4] Twist Bioscience Corp Insider Trading Activity

Twist Bioscience (TWST) COO sells 78K shares under 10b5-1 plan

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

Twist Bioscience Corp (TWST) reported that President and COO Patrick John Finn exercised a stock option for 23,355 shares of common stock at an exercise price of $67.85 per share, eliminating this option position. On the same date, he sold a total of 78,355 shares of common stock in a series of transactions at weighted-average prices ranging from approximately $115.35 to $122.815 per share. These transactions were effected pursuant to a previously adopted Rule 10b5-1 trading plan dated May 18, 2026.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Finn Patrick John
Role President and COO
Sold 78,355 shs ($9.22M)
Approx. gross sale proceeds $9.22M
Approx. exercise cost $1.58M
Type Security Shares Price Value
Exercise Stock Option (right to buy) F1, F9 23,355 $0.00 $0.00
Exercise Common Stock F1 23,355 $67.85 $1.58M
Sale Common Stock F1, F2 33,354 $115.899 $3.87M
Sale Common Stock F1, F3 10,420 $116.8202 $1.22M
Sale Common Stock F1, F4 8,868 $117.697 $1.04M
Sale Common Stock F1, F5 4,500 $119.04 $536K
Sale Common Stock F1, F6 12,917 $119.858 $1.55M
Sale Common Stock F1, F7 6,296 $121.007 $762K
Sale Common Stock F1, F8 2,000 $122.581 $245K
Holdings After Transaction: Stock Option (right to buy) — 0 shares (Direct); Common Stock — 214,678 shares (Direct)
Footnotes (9)
  1. F1. The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 18, 2026.
  2. F2. Represents the weighted average sales price per share. The shares sold at prices ranging from $115.35 to $116.33 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  3. F3. Represents the weighted average sales price per share. The shares sold at prices ranging from $116.37 to $117.36 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  4. F4. Represents the weighted average sales price per share. The shares sold at prices ranging from $117.37to $118.19 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  5. F5. Represents the weighted average sales price per share. The shares sold at prices ranging from $118.505 to $119.45 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  6. F6. Represents the weighted average sales price per share. The shares sold at prices ranging from $119.515 to $120.2 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  7. F7. Represents the weighted average sales price per share. The shares sold at prices ranging from $120.585 to $121.53 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  8. F8. Represents the weighted average sales price per share. The shares sold at prices ranging from $122.00 to $122.815 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  9. F9. The option was 100% exercisable on December 19, 2022.
Shares sold 78,355 shares Total common shares sold by Patrick John Finn on August 18, 2026
Shares exercised 23,355 shares Common shares acquired upon exercise of a stock option on August 18, 2026
Option exercise price $67.85 per share Exercise price for the stock option covering 23,355 shares of common stock
Lowest reported sale range $115.35–$116.33 per share Price range for one tranche of weighted-average sales on August 18, 2026
Highest reported sale range $122.00–$122.815 per share Price range for another tranche of weighted-average sales on August 18, 2026
Option expiration date August 31, 2030 Expiration date of the exercised stock option, which became fully exercisable on December 19, 2022
10b5-1 plan adoption date May 18, 2026 Date on which the Rule 10b5-1 trading plan governing the reported transactions was adopted
Rule 10b5-1 trading plan regulatory
"transactions were affected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy) with underlying Common Stock"
weighted average sales price per share financial
"Represents the weighted average sales price per share. The shares sold at prices"

FAQ

What insider transactions did TWST President and COO Patrick John Finn report?
Patrick John Finn reported exercising a stock option for 23,355 shares of Twist Bioscience Corp common stock at $67.85 per share and selling 78,355 shares of common stock in multiple transactions on August 18, 2026 under a Rule 10b5-1 trading plan.

How many TWST shares did Patrick John Finn sell in this Form 4 filing?
Patrick John Finn sold a total of 78,355 shares of Twist Bioscience Corp common stock on August 18, 2026, according to the Form 4 transaction summary, through several sale transactions described as sales in open market or private transactions.

What was the exercise price of the TWST stock option exercised by Patrick John Finn?
The stock option exercised by Patrick John Finn covered 23,355 shares of Twist Bioscience Corp common stock at an exercise price of $67.85 per share. Following this exercise, the reported remaining balance for that option position was 0 shares.

Over what price ranges were Patrick John Finn’s TWST share sales executed?
The reported sales used weighted average prices with ranges by tranche: from $115.35 to $116.33, $116.37 to $117.36, $117.37 to $118.19, $118.505 to $119.45, $119.515 to $120.2, $120.585 to $121.53, and $122.00 to $122.815 per share.

Were Patrick John Finn’s TWST transactions made under a Rule 10b5-1 trading plan?
Yes. The filing’s Rule 10b5-1 affirmation is checked, and a footnote states the transactions were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Patrick John Finn on May 18, 2026.

When did the exercised TWST stock option become fully exercisable and when would it have expired?
A footnote states the option was 100% exercisable on December 19, 2022, and the option carried an expiration date of August 31, 2030. After the reported exercise of 23,355 shares, the remaining balance for that option was reported as 0 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Finn Patrick John
(Last)(First)(Middle)
C/O TWIST BIOSCIENCE CORPORATION
681 GATEWAY BLVD.
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
President and COO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/18/2026M(1)23,355A$67.85293,033D
Common Stock08/18/2026S(1)33,354(2)D$115.899259,679D
Common Stock08/18/2026S(1)10,420(3)D$116.8202249,259D
Common Stock08/18/2026S(1)8,868(4)D$117.697240,391D
Common Stock08/18/2026S(1)4,500(5)D$119.04235,891D
Common Stock08/18/2026S(1)12,917(6)D$119.858222,974D
Common Stock08/18/2026S(1)6,296(7)D$121.007216,678D
Common Stock08/18/2026S(1)2,000(8)D$122.581214,678D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$67.8508/18/2026M(1)23,355 (9)08/31/2030Common Stock23,355$00D
Explanation of Responses:
1. The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 18, 2026.
2. Represents the weighted average sales price per share. The shares sold at prices ranging from $115.35 to $116.33 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
3. Represents the weighted average sales price per share. The shares sold at prices ranging from $116.37 to $117.36 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
4. Represents the weighted average sales price per share. The shares sold at prices ranging from $117.37to $118.19 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
5. Represents the weighted average sales price per share. The shares sold at prices ranging from $118.505 to $119.45 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
6. Represents the weighted average sales price per share. The shares sold at prices ranging from $119.515 to $120.2 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
7. Represents the weighted average sales price per share. The shares sold at prices ranging from $120.585 to $121.53 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
8. Represents the weighted average sales price per share. The shares sold at prices ranging from $122.00 to $122.815 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
9. The option was 100% exercisable on December 19, 2022.
Remarks:
/s/ Kendra Fox, as Attorney-in-Fact for Patrick John Finn08/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR